Loading...
•
Apr 03, 2022
Pfizer Q1 2022 Earnings Report
Pfizer reported strong financial results, marked by substantial revenue growth and EPS, driven by key products like Comirnaty and Paxlovid. The company reaffirmed its full-year financial guidance and provided updates on various clinical programs.
Key Takeaways
Pfizer's Q1 2022 earnings showcase significant revenue growth, driven by strong performance of Comirnaty and Paxlovid. The company reaffirms its full-year financial outlook, demonstrating confidence in its portfolio and strategic direction.
Q1 2022 revenues reached $25.7 billion, reflecting an 82% operational growth.
Reported diluted EPS was $1.37, and adjusted diluted EPS was $1.62, including a $0.05 negative impact for acquired in-process R&D expenses.
Full-year 2022 financial guidance reaffirmed for revenues of $98.0 to $102.0 billion.
Full-year 2022 adjusted diluted EPS guidance revised to a range of $6.25 to $6.45, reflecting an accounting policy change.
Pfizer
Pfizer
Pfizer Revenue by Segment
Revenue by Segment
Biopharma Revenue
CapyFin.comPfizer CentreOne Revenue
CapyFin.com Forward Guidance
Pfizer reaffirms its full-year 2022 revenue guidance of $98.0 to $102.0 billion and revises adjusted diluted EPS guidance to $6.25 to $6.45, reflecting operational increases offset by foreign exchange impacts and accounting policy changes.
Positive Outlook
- Reaffirms revenue guidance for Comirnaty of approximately $32 billion.
- Reaffirms revenue guidance for Paxlovid of approximately $22 billion.
- Revenue guidance represents 27% operational growth from 2021 revenues at the midpoint.
- Guidance reflects anticipated operational increases in COVID-19-related products.
- Incremental investments planned in COVID-19-related vaccine and anti-viral life-cycle management programs.
Challenges Ahead
- Approximately $2 billion of negative foreign exchange impacts on revenues.
- ~$1 billion unfavorable impact from foreign exchange on Comirnaty revenue.
- ~$0.5 billion unfavorable impact from foreign exchange on Paxlovid revenue.
- Adjusted diluted EPS revised to reflect an $0.11 negative impact for an accounting policy change.
- Anticipated negative revenue impact of $0.7 billion due to recent and expected generic and biosimilar competition.
Revenue & Expenses
Visualization of income flow from segment revenue to net income